JCEM: GLP-1 receptor agonist syagogis for obesity, polycystic ovary syndrome and infertility
-
Last Update: 2020-06-25
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Obesity is responsible for the increased risk of secondary and infertilityObese women had poorer reproductive outcomes regardless of the way they conceiveed, while higher body mass index (BMI) was associated with poorer reproductive outcomesPolycystic ovary syndrome (PCOS) is one of the main causes of infertility, and many women with PCOS are also associated with overweight or obesity, a recent study published in journal Journal of Clinical Endocrinology and Metabolism, an authoritative journal for endocrine and metabolic diseases, aims to describe the mechanisms that lead to infertility and PCOS in obese/overweight women, with a focus on GLP-1 receptor agonist (GLP-1 RA) as a treatment option for obese women with PCOSweight loss is the most important factor affecting fertility and pregnancy outcomesCurrent experimental and clinical evidence suggests a potential pathophysiological link between obesity, changes in GLP-1 dynamics and PCOS pathogenesisBased on positive results in obese patients with or without diabetes, the efficacy of GLP-1 RA (mainly liraglutide) in women with obesity has been studied, either individually or in combination with metforminSeveral studies have shown that weight loss and significant reductions in testosterone are associated with insulin resistance parameters and improved menstrual proceduresit is clear that GLP-1RA's weight loss effect provides an opportunity to broaden treatment options for PCOS patients
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![Biggest manufacturer of Pyridine, 2-methyl-5-[(2S)-1-methyl-2-pyrrolidinyl]-](https://file.echemi.com/fileManage/upload/goodpicture/20230905/biggest-manufacturer-of-pentaerythritol-glycidyl-ether_b20230905173933816.jpg)
